<DOC>
	<DOCNO>NCT00504764</DOCNO>
	<brief_summary>Summary Acute promyelocytic leukemia define characteristic morphology ( AML FAB M3/M3v ) , specific translocation ( 15 ; 17 ) molecular correlate ( PML/RARa RARa/PML ) . Thereby separate form acute leukemia . By all-trans retinoic acid combination chemotherapy cure rate 70 80 % reach . On average , 10 % patient still die early phase treatment 20 30 % relapse . Molecular monitoring minimal residual disease ( MRD ) qualitative nest RT-PCR quantitative REAL-time PCR PML/RARa allow follow individual kinetics MRD identify patient imminent hematological relapse . A standardized treatment patient relapse APL yet establish . With arsenic trioxide ( ATO ) monotherapy remission rate 80 % achieve long-lasting molecular remission describe . The drug mostly well tolerate . ATO exert dose dependent dual effect APL blast , apoptosis higher partial differentiation low concentration . ATO also successfully administer allogeneic autologous transplantation . ATO approve treatment relapse refractory APL Europe USA . After remission induction , several option postremission therapy Previous study show risk relapse high patient treat ATO postremission monotherapy , receive ATO plus chemotherapy transplantation ( TPH ) . Also , compare chemotherapy , ATO induction consolidation favorable impact posterior response transplantation . It due low toxicity best quality remission TPH . It seem well , reason , intensification TPH ( autologous allogenic ) patient relapse APL treat ATO . For another hand , patient candidate TPH treat ATO combine active agent APL , ATRA , anthracyclines Mylotarg</brief_summary>
	<brief_title>Treatment Relapsed Promyelocytic Leukemia With Arsenic Trioxide ( ATO )</brief_title>
	<detailed_description>Induction ATO 0.15 mg/kg/día IV continuous perfusion 1-2 hours/day complete response ( CR ) maximum 60 day . Oral hydroxyurea treatment ( initial dose 2 g/day ) recommend patient leucocyte count relapse &gt; 10x109/L two first week induction . Isolated molecular relapse patient treat ATO ( dose ) 5 day week , 6 week . Consolidation ATO 0.15 mg/kg/día IV 5 day week , 5 week , combine oral ATRA 45 mg/m²/day 5 week . Post-consolidation therapy TPH ( autologous allogenic ) candidate patient . In case molecular remission , recommend autologous-TPH . Patients candidate auto-TPH alo-TPH , follow treatment ATO cycle + ATRA +/- Mylotarg . 1 . Option Alo-TPH If PCR post-consolidation negative recommend auto-TPH . However , alo-TPH decide , do immediately without precede chemotherapy . If PCR post-consolidation positive , do alo-TPH . 2 . Option Auto-TPH If PCR post-consolidation negative administer one cycle MTZ + Ara-C follow auto-TPH . In cas failure : ) patient autologous stem cell preserve ( PCR negative ) suitable auto-TPH ; b ) patient HLA-compatible donor suitable allogenic stem cell transplantation transplant ; c ) Patients eligible allogenic autologous transplantation , receive various cycle ATO + ATRA combine Mylotarg . If PCR post-consolidation positive patient eligible allogenic TPH , do allogenic TPH . If patient eligible allogenic TPH dont compatible donor , administrate one cycle MTZ + Ara-C collect stem cell . Autologous transplantation do cycle , molecular remission obtain . No molecular remission enough stem cell collection , patient follow treatment subsequent cycle ATO + ATRA combine Mylotarg . 3 . ATO + ATRA combine Mylotarg Patients eligible autologous TPH allogenic TPH follow treatment subsequent cycle ATO + ATRA combine Mylotarg . If Mylotarg possible , treatment subsequent cycle ATO + ATRA . ATO + ATRA + Mylotarg : Mylotarg 6 mg/m2 day 1 , ATO 0.15 mg/kg day 1 5 8 12 , ATRA 45 mg/m2/d day 1 15 . Doses mylotarg reduce 3 mg/m2 patient age 60 year . Administration 3 cycle month interval , follow 3 6 cycle ATO + ATRA without Mylotarg . After , ATRA 45 mg/m2/d 15 day every 3 month complete two year maintenance . ATO + ATRA : ATO 0.15 mg/kg day 1 5 8 12 , ATRA 45 mg/m2/d day 1 15 , every 29 day . Administration 9 cycle , follow ATRA 45 mg/m2/d 15 day every 3 month complete two year maintenance .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>ECOG ≤ 3 . Patients first subsequent hematological molecular relapse APL Persistence positive PCR ( positive PCR 3 consolidation cycle first line therapy ) . Diagnostic measure Confirmation relapse RTPCR PML/RARa , cytogenetics , FISH positive PGM3 . Age 18 year ( No upper age limit ) Informed consent patient ECOG 4 . Heart failure NYHA grade III IV . Renal hepatic failure WHO grade ³III Positive HIV . Psychological dysfunction Associated active neoplasia Pregnancy . Arsenic Hypersensibility . QTcinterval prolong 460 msec therapy ( normal electrolyte , drug prolong QTinterval )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Relapsed Acute Promyelocytic Leukemia</keyword>
	<keyword>Arsenic Trioxide</keyword>
</DOC>